IO Biotech | 10-Q: FY2025 Q3 Revenue: USD 0

LB filings
2025.11.14 14:14
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.13, beating the estimate of USD -0.375.

EBIT: As of FY2025 Q3, the actual value is USD -18.72 M.

Operational Metrics

  • Net Loss: For the three months ended September 30, 2025, the net loss was - $8.4 million, compared to - $24.0 million for the same period in 2024, representing a decrease of 65.1%.
  • Research and Development Expenses: For the three months ended September 30, 2025, R&D expenses were $13.7 million, a decrease of 31.9% from $20.2 million in the same period in 2024.
  • General and Administrative Expenses: For the three months ended September 30, 2025, G&A expenses were $5.6 million, a decrease of 11.3% from $6.3 million in the same period in 2024.

Cash Flow

  • Net Cash Used in Operating Activities: For the nine months ended September 30, 2025, net cash used in operating activities was - $61.4 million, compared to - $62.7 million for the same period in 2024.
  • Net Cash Provided by Financing Activities: For the nine months ended September 30, 2025, net cash provided by financing activities was $32.8 million.

Unique Metrics

  • Change in Fair Value of Warrants: For the three months ended September 30, 2025, the change in fair value of warrants was $9.8 million.

Future Outlook and Strategy

  • Core Business Focus: The company plans to continue the dialogue with the FDA to align on the design of a potential new registrational study for Cylembio® in patients with advanced melanoma and plans to discuss the data from the IOB-013 study with European regulators.
  • Non-Core Business: The company announced a restructuring and workforce reduction plan to reduce operations and preserve financial resources, resulting in a reduction of the workforce by approximately 50%.

Priority

  • The company is actively seeking additional capital, including through public or private equity or debt financing, strategic collaborations, licensing, and other arrangements to fulfill its operating and capital requirements for the next 12 months.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.